Jayanetti, Roxby, and Badrick: Key incidents identified by the Royal College of Pathologists of Australasia Quality Assurance Programs Key Incident Monitoring and Management EQA program

Introduction

Pre- and postanalytical errors represent most errors in the total testing cycle leading to increased risk of misdiagnosis and treatment of patients (1-3). Identification, phlebotomy, collection tube and sample preservation and transport related errors are common sources of error, particularly when the specimen collection staff are not laboratory-controlled (4). Postanalytical errors mainly involve delayed or incomplete delivery of results to referring doctors. Despite this, few benchmarking EQA programs are available for medical laboratories to assess these error rates objectively (5, 6). Indicators of the extra-analytical phases of the Total Testing Process (TTP) have been developed in several countries, such as Australia and New Zealand, The US Brazil, and Spain/Catalonia, and other surveys and programs have been promoted in the UK, China and Croatia (7-14). In 2008, the IFCC launched a Working Group named “Laboratory Errors and Patient Safety” (WG: LEPS) to identify Quality Indicators (QIs) and related quality specifications that (i) produce benchmarks from comparing laboratories, (ii) promote error reduction and (iii) increase patient safety. The IFCC has developed QIs, which laboratories in several countries have evaluated, and the WG: LEPS has reported preliminary results (15-17).

To reduce pre- and post-analytical error, laboratories need to focus on these phases of the total testing cycle with relevant QIs and benchmarks from external sources (18-20). As with any form of benchmarking, laboratories must collect and track their QIs and then compare them against the relevant peer group. Initially, this ensures they collect the same data as their peers, then compare their performance. If there are significant differences after data collection error has been eliminated, then a review of the process is warranted. To ensure there is confidence in this comparison, a sufficiently large peer group collecting the same QIs needs to be available, and the data collection needs to be regular enough to detect trends (21).

But collecting QI data in pathology can be tedious. Benchmarking processes are far more difficult than standard analytical EQA because measurement may be complex and not standardised, data collection may not be easy, and targets are unavailable. As with many benchmarking exercises, there have been problems with the definitions and robustness of the QIs. Key Incident Monitoring and Management EQA Program has tried to ensure that participants collect and submit the same data for each of the QIs. While progress has been made in this direction, the data is still not always homogeneous. One of the aims of the KIMMS program is to produce a list of key incidents that should be tracked by an LIS. Also, changing a process is more difficult than identifying an error in an assay system.

The Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) Key Incident Monitoring and Management EQA Program (KIMMS) started in 2011 and aims to monitor the pre- and post-analytical phase of the laboratory quality system (7). Key Incident Monitoring and Management EQA Program measures risks from incidents recorded by participant laboratories and compares these to those of peer organisations. Incidents and risks are related but not equal (22). The program assesses risk based on the consequences to the patient, the probability that the event will occur, and how easy it is to detect the incident. A reduction in probability or an increase in detectability can reduce the risk. A two-phase risk calculation is used in KIMMS, where a harm factor equals consequences multiplied by likelihood (21). The risk score equals harm times detectability (23).

As an example of this risk score process, we present this case where the overall performance summary highlights any “incident” that recorded a rate greater than 80% of all participants. This is presented in a table, which includes columns for the consequence, probability and detectability rating (Tables 1-3Table 2Table 3). The KIMMS Advisory Committee has pre-determined the consequence rating, so this field is pre-populated.

Table 1

Example risk score table from the KIMMS report

Parameter out of allowable limits Consequence rating Probability rating Detectability rating Risk score Organisational response
Inpatient - hemolysis rate = 400 2 5 1 10 Example: Although this is a low-risk incident, high compared to peers and to our collectors (0.2). Meeting with hospital organised 7/10/22
Table 2

KIMMS consequence scale

Scale Name Definition
1 Negligible/Minimal Minimal, delay, inconvenience
2 Marginal/Minor Recollect required
3 Significant/Moderate Delayed management (non-malignant) and/or medical treatment
4 Serious/Major Delayed diagnosis (malignant) and/or surgical treatment
5 Critical/Catastrophic Serious harm to multiple patients and/or patient death
Table 3

KIMMS probability scale

Scale Name Example Definition
1 Rare < 1/year
2 Unlikely 1 per year
3 Occasional 1 per month
4 Likely 1 per week
5 Frequent 1 per day or more

Results review

It is recommended that participants review their results by applying the probability and detectability rating to determine the risk score (Tables 2-4Table 3Table 4). The risk score is calculated by multiplying the three ratings (consequence rating x probability rating x detectability rating). The risk score can be used as a guide to organisational risk; from that, a decision is made as to the next step(s).

Table 4

KIMMS detectability scale

Scale Name Definition
1 Detected > 95%
2 Most detected 75-95%
3 Half detected 25-75%
4 Most not detected < 5-25%
5 Not detected < 5%

In the above example, the consequence, probability and detectability rating give a risk score of 10. This would be considered low risk. Apart from flagging that the risk is higher than other participants’ inpatient collections, it is unlikely that any further immediate action is required. This incident should be monitored closely to ensure it does not deteriorate.

Risk score

The score is calculated by multiplying the consequences (Table 1) x probability (Table 2) x detectability (Table 3).

The purpose of this paper is to report the most common incidents that have been detected in the 2024 KIMMS program.

Materials and methods

The KIMMS program has four surveys a year, collecting data from the previous three months, with preanalytical and postanalytical incident reporting of 35 incident types that have been pre-determined by the RCPAQAP KIMMS Advisory Committee. Data is submitted via the RCPAQAP myQAP portal, where result entry instructions are included. Participants are asked to capture the number of episodes and the number of incidents per quarter of the year.

Data is then analysed using RCPAQAP in-house data analysis software, where each specific incident reported to KIMMS is calculated per 100,000 episodes (number of incidents divided by the number of episodes, multiplied by 100,000), known as the rate. Incident rates are compared to peer groups and flagged red if outside the best performers, which is set at 80% of all results. This summary will focus on 2024 data.

A single request usually covers an episode and may contain one or more samples. It may include more than one request, but the samples are collected simultaneously, i.e., samples received together in a bag with a request form equal one episode.

Participants range from small to large pathology laboratories, where size is determined by the number of episodes per quarter (small: < 100,000, medium: 100,000-500,000, large: > 500,000). This data is also collected for each submission. The participants include a mix of public and private organisations from across Australia and a couple of international sites.

Patient sources

The KIMMS program was renewed in 2023 to allow for further comparison by separating data into categories such as the patient source (Inpatient/Outpatient/Community/Emergency Department (ED)).

The Inpatient patient source refers to pathology testing performed on an admitted hospital patient (public or private hospital). The Outpatient source includes pathology requests and specimens that are collected while a patient attends a clinic run by a hospital. This includes day patients and cancer treatment centres. The Emergency Department patient source refers to pathology testing performed on a patient attending an Emergency Department (ED)/Emergency Room (ER)/Accident and Emergency (A&E)/Casualty ward/department. The community patient source is for when the pathology request is generated anywhere, but the specimens are collected in settings other than the previously mentioned patient sources. This includes doctors’ surgeries, designated collection centres (even within a hospital), nursing homes, home visits, and workplace collections.

The KIMMS program also offers a Mixed patient source option for those organisations that are unable to differentiate their data between patient sources. In the final calculations, these are analysed with a total of all results.

Results

The four 2024 surveys received an average of 111 responses, with 55,329,998 episodes recorded and 1,496,708 incidents identified.

Table 5 summarises the total episodes and incidents reported per survey. Table 6 summarises the key results for the top three incidents from all sites, and Table 7 shows the key results per size of organisation. Tables 8-10Table 9Table 10 display the average 80th percentile cut-off rates and standard deviations (SDs) per patient source and the Mixed/Total category for the Test Request/Collection incident categories, as well as the Test Registration/Analytical/Postanalytical incident categories from the four 2024 KIMMS surveys.

Table 5

The total number of episodes and incidents reported in each 2024 KIMMS survey

Total episodes Total incidents
Survey 1 11,930,241 274,277
Survey 2 13,123,033 295,720
Survey 3 14,832,081 484,514
Survey 4 15,444,643 442,197
Table 6

The top three incidents with the highest incident rates in 2024, per the source of the patient

Inpatient Outpatient Community Emergency Department Mixed/Total
Incorrect specimen type or container or acid (200) Incorrect specimen type or container or acid (160) No specimen received (272) Incorrect specimen type or container or acid (344) No specimen received (271)
Specimen clotted or other clotting issue (250) Essential clinical indication for a test is not provided (227) Essential clinical indication for the test is not provided (130) Specimen clotted or other clotting issue (428) Insufficient specimen (126)
Specimen hemolysed (230) No specimen received (320) Insufficient specimen (92) Specimen hemolysed (711) Specimen hemolysed (127)
Values in brackets represent the rates.
Table 7

The top three incidents with the highest incident rates in 2024, per the size of the organisation (episodes per quarter)

Small organisation
(< 100,000 episodes)
N = 89
Medium organisation (100,000-500,000 episodes)
N = 13
Large organisation
(> 500,000 episodes)
N = 9
Essential collection date/time not provided or discrepant between specimen and request (401) No specimen received (407) No specimen received (528)
Incorrect specimen type or container or acid (589) Insufficient specimen (322) Essential clinical indication for the test is not provided (331)
Specimen clotted or other clotting issue (466) Specimen clotted or other clotting issue (411) Specimen hemolysed (280)
The “N” value refers to the average number of submissions per survey in 2024 that selected that particular size of organisation.
Table 8

Average 80th percentile cut-off rates per patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys

Inpatient Outpatient Community ED
Clarification of tests required 109.4 140.2 0.9 263.6
Insufficient requester details or signature missing 3.2 0.0 7.5 8.1
Unlabelled specimen or request 210.4 247.5 128.6 272.2
Insufficient patient ID on specimen and/or request 113.4 91.3 85.2 100.4
ID mismatch between specimen and/or request 161.8 100.9 61.9 200.6
Specimens from wrong patient (WSIT) 35.5 24.1 1.6 44.8
Essential collection date/time not provided or discrepant between specimen and request 14.1 9.3 2.3 34.3
Essential signature missing or discrepant on transfusion sample and/or request 113.6 83.0 17.9 185.6
Essential clinical indication for test not provided 41.7 78.8 40.3 18.5
Essential specimen type/site not provided 6.0 0.0 10.9 3.3
Incorrect patient preparation 8.2 0.0 12.2 9.0
Incorrect specimen type or container or acid 228.7 158.0 75.5 208.3
No specimen received 421.4 521.7 378.5 589.4
Insufficient specimen 335.5 252.6 147.8 458.2
Specimen incorrect fill leading to incorrect specimen:additive ratio 153.7 88.8 42.0 199.3
Specimen clotted or other clotting issue 385.4 161.6 51.1 679.7
Specimen contaminated - non-microbiological 40.7 17.8 4.6 33.6
Specimen contaminated - microbiological 0.0 0.0 0.1 1.8
Specimen hemolysed 75.1 37.1 44.1 416.0
Specimen leaking 0.0 0.0 3.8 13.1
Incorrect transport / storage temperature / handling 46.5 65.2 50.9 33.0
Transport delay leading to specimen being too old to test 109.7 135.1 45.8 82.6
Table 9

Average 80th percentile cut-off rates for the Mixed/Total patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys

Mixed/Total
Clarification of tests required 44.3
Insufficient requester details or signature missing 9.1
Unlabelled specimen or request 227.2
Insufficient patient ID on specimen and/or request 78.0
ID mismatch between specimen and/or request 120.5
Specimens from wrong patient (WSIT) 28.0
Essential collection date/time not provided or discrepant between specimen and request 12.9
Essential signature missing or discrepant on transfusion sample and/or request 102.4
Essential clinical indication for test not provided 53.1
Essential specimen type/site not provided 11.1
Incorrect patient preparation 11.0
Incorrect specimen type or container or acid 178.7
No specimen received 425.7
Insufficient specimen 290.4
Specimen incorrect fill leading to incorrect specimen: additive ratio 129.4
Specimen clotted or other clotting issue 359.8
Specimen contaminated - non-microbiological 26.7
Specimen contaminated - microbiological 0.0
Specimen hanalytemolysed 83.9
Specimen leaking 8.6
Incorrect transport / storage temperature / handling 49.4
Transport delay leading to specimen being too old to test 94.9
Table 10

Average 80th percentile cut-off rates for all results for the Test Registration/Analytical/Postanalytical incident categories from the four 2024 KIMMS surveys

Total
Incorrect unique specimen identifier 8.4
Patient ID - wrong patient 7.1
Errors in transcription of patient demographic information 31.7
Incorrect or missed tests 183.1
Incorrect or missing specimen type, site, collection time 26.0
Incorrect requesting or copy doctor 131.7
Internal laboratory process incident - unfixable 43.0
Within laboratory ID error 6.4
Intra or inter-laboratory specimen lost or misplaced - irreplaceable 0.2
Intra or inter-laboratory specimen lost or misplaced - replaceable 10.0
Failures of clinical handover high-risk (critical) results 0.1
Failures of clinical handover non-critical results 0.1
Amended reports, significant patient impact 47.7

Figures 1-3Figure 2Figure 3 are bar graphs highlighting the average 80th percentile cut-off rates per patient source and the Mixed/Total category for the Test Request/Collection incident categories, as well as the Test Registration/Analytical/Postanalytical incident categories from the four 2024 KIMMS surveys.

Figure 1

Average 80th percentile cut-off rates per patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys.

bm-36-1-010701-f1
Figure 2

Average 80th percentile cut-off rates for the Mixed/Total patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys.

bm-36-1-010701-f2
Figure 3

Average 80th percentile cut-off rates for all results for the Test Registration/Analytical/Post-Analytical incident categories from the four 2024 KIMMS surveys.

bm-36-1-010701-f3

Discussion

The findings from the 2024 program are that the incident “No specimen received” appears to have the highest 80th percentile across the patient sources. The cost of a recollection is significant, both in organisational cost and patient time (24). More importantly, it is an error that can be reduced once identified. Suggested mechanisms to reduce this incident would be computer-generated, or manual checklists of collection tubes required for a given set of requested tests.

The commonest site of error is the ED, with an 80th percentile overall. The primary cause is the non-professional collector and the collection process (4, 25-27). The solution could include better training of nursing and medical staff in the ED, though this has had poor long-term effects (25). The issue may be costly enough for the organisation to place phlebotomists in ED (28).

The 80th percentiles are consistent for all incidents throughout the year, meaning the occurrence of incidents is also consistent, validating the data collection process. The 80th percentiles are greater overall for incidents that fall under the Collection incident category, such as “No specimen received”, “Insufficient specimen”, “Specimen clotted” and “Specimen hemolysed”. Sites that perform greater than the 80th percentile have the incidents flagged for review. It is then up to the participants to calculate the risk of the incident to their organisation by referring to our KIMMS Matrix Table (https://rcpaqap.com.au/kimms-matrix-table/), which comprises consequence, probability and detectability. Specific incidences, such as WSIT, may have lower rates reported than the actual values, as the detectability of such incidences is low. This is why in the KIMMS risk matrix table, a higher value for detectability can be assigned to increase the overall risk score and severity of these incidents.

The KIMMS program has been operating since 2011 with several improvements (7, 21, 23). Significant findings and trends have been separately published (21, 29). This experience of participants reporting using standardised definitions of incidents has led to consistent data collections as can be seen from year-on-year results. It has taken some years for this to occur, as there is much variation in what laboratories call episodes and what their capability is to accurately collect these data. The QIs used are relevant to Australian laboratory practice and share commonality with the IFCC set. It is difficult to compare results from different publications as many are one-off surveys rather than a system of regular data collection.

The limitations of this program’s data collection process include some manual data collection processes and likely missing data for some QIs, such as WSIT, because the laboratory is unable to identify these errors (30).

In conclusion, the KIMMS data provide valuable, regular and reproducible benchmarking data for the pre- and post-analytical phases of the total testing cycle. The incidents represent areas where the risk to patients can be reduced.

Appendices

Appendix
Table 11

All incidents measured in the KIMMS program and explanation of each incident

Categories Incident Explanation of incident
Test request Clarification of tests required Collector or laboratory required to contact requestor to confirm test(s) requested as information not clear or illegible on request
Insufficient requester details or signature missing This occurs when the information supplied is not sufficient to know which doctor should receive the report, or the request is not signed when a signature is required
Unlabelled specimen and/or request This is when sample or request has no patient identifiers
Collection: Identification Insufficient patient ID specimen and/or request Minimum identifiers are full name and DOB. Three identifiers may be required e.g., transfusion samples
ID mismatch between specimen and/or request ID on specimen label does not match accompanying request form or electronic order
Specimen from wrong patient (WSIT) Labelling of specimen and request are concordant, but the actual sample in the container is from a different patient
Essential collection date and/or time not provided or discrepant between specimen and request Specimen and form must align especially essential for a Transfusion request
Collection: Documentation Essential signature missing or discrepant on transfusion sample and/or request This refers to collector and patient signature
Essential clinical indication for test not provided Collector fails to record the clinical indication for the test that is required by the laboratory to aid in the interpretation of results
Essential specimen type/site not provided Specimen type and/or site not provided when information is required to aid in appropriate testing and interpretation of results by the laboratory
Incorrect patient preparation Patient not fasting, medication taken instead of being withheld, preparation procedure for test not followed
Incorrect specimen type or container or acid Incorrect specimen type collected/submitted for test request
No specimen received No sample received to do the test
Insufficient specimen Insufficient specimen to do any or all tests requested
Collection: Specimen Specimen incorrect fill leading to incorrect specimen: additive ratio Under or overfilled Citrate (COAG) tubes
Specimen clotted or other clotting issue Most commonly EDTA tubes, but any tube with anti-coagulant may be clotted
Specimen contaminated - non microbiological E.g. diluted from IV drip; or order of draw incorrect
Specimen contaminated - microbiological Contaminated microbiology samples that require a recollection
Specimen hemolysed Hemolysis should be counted if the sample is deemed unsuitable for one or more tests due to the level of hemolysis
Specimen leaking Any leakage should be recorded, even if there is still sufficient specimen to do the test
Collection: Transport, storage and handling Incorrect transport/storage temperature/handling Stored and/or transported at wrong temperature or handling not in accordance with documented procedure
Transport delay leading to specimen being too old to test Any delay in transport
Incorrect unique specimen identifier Also known as episode; laboratory or accession number. It is the unique identifier for that specimen from that patient collected/submitted on that date/time
Patient ID wrong patient This occurs when the wrong patient is chosen at data entry from a list of patients with the same, or similar name. Request associated to incorrect patient demographics
Test registration Error in transcription of patient demographic information This occurs when information is incorrectly entered from a request. Registration data manually entered
Incorrect or missed tests Test on request form not added at registration or incorrect test added
Incorrect or missing specimen type, site, collection time This is when the information is available on the request form or electronic order but is not entered into the LIS
Incorrect requesting or copy doctor Referring clinician or copy to clinician not registered to receive copy of the report
Internal laboratory process incident - unfixable This refers to any incident that happens after the sample has arrived at the laboratory that is not directly related to performing the test
Analytical Within laboratory ID error Error transferring patient Identification within the laboratory
Intra or inter-laboratory specimen lost or misplaced - irreplaceable Specimens lost during intra and inter-laboratory transfer that are irreplaceable
Intra or inter-laboratory specimen lost or misplaced - replaceable Specimens lost during intra and inter-laboratory transfer that can be recollected
Failure of clinical handover high-risk (critical) results Failure to communicate high-risk results to the relevant party within agreed guidelines as documented within your organisation
Postanalytical Failure of clinical handover non-critical results Requests to re-send copy of report due to non-receipt by the requestor, including referring laboratories
Amended report. Significant patient impact This is amended report due to a diagnostic error or incorrect result being released
DOB - date of birth. LIS - laboratory information system.

Notes

[1] Conflicts of interest Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References

1 

Plebani M. Errors in laboratory medicine and patient safety: The road ahead. Clin Chem Lab Med. 2007;45:700–7. https://doi.org/10.1515/CCLM.2007.170

2 

Carraro P, Plebani M. Errors in a stat laboratory: types and frequencies 10 years later. Clin Chem. 2007;53:1338–42. https://doi.org/10.1373/clinchem.2007.088344

3 

Plebani M. Exploring the iceberg of errors in laboratory medicine. Clin Chim Acta. 2009;404:16–23. https://doi.org/10.1016/j.cca.2009.03.022

4 

McCaughey EJEJ, Vecellio E, Lake R, Li L, Burnett L, Chesher D, et al. Key factors influencing the incidence of hemolysis: A critical appraisal of current evidence. Crit Rev Clin Lab Sci. 2017;54:59–72. https://doi.org/10.1080/10408363.2016.1250247

5 

Sciacovelli L, Plebani M. The IFCC Working Group on laboratory errors and patient safety. Clin Chim Acta. 2009;404:79–85. https://doi.org/10.1016/j.cca.2009.03.025

6 

Kristensen GBB, Aakre KM, Kristoffersen AH, Sandberg S. How to conduct External Quality Assessment Schemes for the pre-analytical phase? Biochem Med (Zagreb). 2014;24:114–22. https://doi.org/10.11613/BM.2014.013

7 

Badrick T, Gay S, Mackay M, Sikaris K. The key incident monitoring and management system - History and role in quality improvement. Clin Chem Lab Med. 2018;56:264–72. https://doi.org/10.1515/cclm-2017-0219

8 

Nakhleh RE, Souers RJ, Bashleben CP, Talbert ML, Karcher DS, Meier FA, et al. Fifteen years’ experience of a college of American pathologists program for continuous monitoring and improvement. Arch Pathol Lab Med. 2014;138:1150–5. https://doi.org/10.5858/arpa.2014-0148-OA

9 

Meier FA, Souers RJ, Howanitz PJ, Tworek JA, Perrotta PL, Nakhleh RE, et al. Seven Q-Tracks monitors of laboratory quality drive general performance improvement: Experience from the College of American Pathologists Q-Tracks program 1999-2011. Arch Pathol Lab Med. 2015;139:762–75. https://doi.org/10.5858/arpa.2014-0090-CP

10 

Shcolnik W, De Oliveira CA, De São José AS, De Oliveira Galoro CA, Plebani M, Burnett D. Brazilian laboratory indicators program. Clin Chem Lab Med. 2012;50:1923–34. https://doi.org/10.1515/cclm-2012-0357

11 

Kirchner MJ, Funes VA, Adzet CB, Clar MVD, Escuer MI, Girona JM, et al. Quality indicators and specifications for key processes in clinical laboratories: A preliminary experience. Clin Chem Lab Med. 2007;45:672–7. https://doi.org/10.1515/CCLM.2007.122

12 

Barth JH. Clinical quality indicators in laboratory medicine: A survey of current practice in the UK. Ann Clin Biochem. 2011;48:238–40. https://doi.org/10.1258/acb.2010.010234

13 

Barth JH. Clinical quality indicators in laboratory medicine. Ann Clin Biochem. 2012;49:9–16. https://doi.org/10.1258/acb.2011.011126

14 

Simundic AM, Topic E. Quality Indicators. Biochem Med (Zagreb). 2008;18:311–9. https://doi.org/10.11613/BM.2008.027

15 

Sciacovelli L, Padoan A, Aita A, Basso D, Plebani M. Quality indicators in laboratory medicine: State-of-the-art, quality specifications and future strategies. Clin Chem Lab Med. 2023;61:688–95. https://doi.org/10.1515/cclm-2022-1143

16 

Plebani M. Quality indicators to detect pre-analytical errors in laboratory testing. Clin Biochem Rev. 2012;33:85–8.

17 

Sciacovelli L, Lippi G, Sumarac Z, West J, Garcia Del Pino Castro I, Furtado Vieira K, et al. Quality Indicators in Laboratory Medicine: The status of the progress of IFCC Working Group “laboratory Errors and Patient Safety” project. Clin Chem Lab Med. 2017;55:348–57. https://doi.org/10.1515/cclm-2016-0929

18 

Aita A, Sciacovelli L, Plebani M. Extra-analytical quality indicators - where to now? Clin Chem Lab Med. 2018;57:127–33. https://doi.org/10.1515/cclm-2017-0964

19 

Plebani M, Sciacovelli L, Aita A, Padoan A, Chiozza ML. Quality indicators to detect pre-analytical errors in laboratory testing. Clin Chim Acta. 2014;432:44–8. https://doi.org/10.1016/j.cca.2013.07.033

20 

Sciacovelli L, Padoan A, Aita A, Basso D, Plebani M. Quality indicators in laboratory medicine: State-of-the-art, quality specifications and future strategies. Clin Chem Lab Med. 2023;61:688–95. https://doi.org/10.1515/cclm-2022-1143

21 

Gay S, Badrick T. Changes in error rates in the Australian key incident monitoring and management system program. Biochem Med (Zagreb). 2020;30:020704. https://doi.org/10.11613/BM.2020.020704

22 

Badrick T, Gay S, McCaughey EJEJ, Georgiou A. External quality assessment beyond the analytical phase: An Australian perspective. Biochem Med (Zagreb). 2017;27:73–80. https://doi.org/10.11613/BM.2017.009

23 

Gay S, Pope B, Badrick T, Whiley M. Review of current incidents and risk calculations used in the Royal College of Australasian Pathologists Key Incident Management and Monitoring Systems - a system that could be used by all Australasian medical laboratories, and easily adapted to worldwide use. Biochem Med (Zagreb). 2022;32:010702. https://doi.org/10.11613/BM.2022.010702

24 

Green SF. The cost of poor blood specimen quality and errors in preanalytical processes. Clin Biochem. 2013;46:1175–9. https://doi.org/10.1016/j.clinbiochem.2013.06.001

25 

Howanitz PJ, Lehman CM, Jones BA, Meier FA, Horowitz GL. Clinical laboratory quality practices when hemolysis occurs. Arch Pathol Lab Med. 2015;139:901–6. https://doi.org/10.5858/arpa.2014-0252-CP

26 

Heyer NJ, Derzon JH, Winges L, Shaw C, Mass D, Snyder SR, et al. Effectiveness of practices to reduce blood sample hemolysis in EDs: A laboratory medicine best practices systematic review and meta-analysis. Clin Biochem. 2012;45:1012–32. https://doi.org/10.1016/j.clinbiochem.2012.08.002

27 

Lee H, Lee H, Kim C, Shin H, Lee I, Kim Y. Hemolysis Control in the Emergency Department by Interventional Blood Sampling. J Pers Med. 2023;13:651. https://doi.org/10.3390/jpm13040651

28 

Burns ER, Yoshikawa N. Hemolysis in Serum Samples Drawn by Emergency Department Personnel versus Laboratory Phlebotomists. Lab Med. 2002;5:378–80. https://doi.org/10.1309/PGM4-4F8L-2P1M-LKPB

29 

Gay S, Sikaris K. Badrick. Tony. Reporting Critical Pathology Results - what is the current state of play in Australian Laboratories? An opinion based on findings of a KIMMS audit. Australian Journal of Medical Science. 2019;40:126–30.

30 

Dunbar NM, Kaufman RM. Factors associated with wrong blood in tube errors: An international case series – The BEST collaborative study. ransfusion. 2022;62:44–50. https://doi.org/10.1111/trf.16716